OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF EVOLOCUMAB FOR LDL-C REDUCTION, AS ADD-ON TO DIET AND LIPID-LOWERING THERAPY, IN PEDIATRIC SUBJECTS FROM 10 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- Registry ID
- 20120124
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2018-01-29
- Completion date
- 2019-12-19
- Last update
- 2016-02-03
Conditions
- HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Related clinical trials
- A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFECT OF AZD0780 ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA
- OPEN-LABEL, PHASE LB, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY OF
VERVE-102 ADMINISTERED TO PATIENTS WITH HETEROZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA OR PREMATURE CORONARY ARTERY DISEASE WHO REQUIRE ADDITIONAL
LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL
- SAFETY AND EFFECTIVENESS OF EVINACUMAB FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN A REAL LIFE SETTING IN CANADA
- PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ARO-ANG3 IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ISIS 703802 (AKCEA-ANGPTL3LRX) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- AN 8-WEEK OPEN-LABEL, SEQUENTIAL, REPEATED DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AIIROCUMAB IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA FOLLOWED BY AN EXTENSION PHASE
View on source registry